209P-Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
Published date:
09/13/2021
Excerpt:
Patients have HER2-expressing or -amplified solid tumors...In response-evaluable patients (N=14), best overall response was PR (n=1), SD (n=3), and PD (n=10)….Based on preliminary safety data, SBT6050 given alone or in combination with pembrolizumab has a manageable safety profile.